Compounds for treating infections

A method for treating an infection in a subject in need thereof, comprising administering to the subject a compound having of Formula (1), Formula (2), Formula (3), or Formula (4):

• or a pharmaceutically acceptable salt thereof, wherein:
• R1 is OR1a or N(R1a)2, wherein R1a is in each case independently selected from H, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
• R2 is H or OH;
• Z is Z1—X, wherein Z1 is null, NH, S, O, CH2, CH2O, OCH2, OCH2O, CH2NH, NHCH2, CH2S, SCH2, X is P(O)(ORp)2, SO2N(Rp)2, SO2Rp*, wherein Rp is in each case independently selected from H or C1-8alkyl, and Rp* is C1-8alkyl;
• one of Y1 and Y2 is NH2, and the other is Y*—Ar, wherein Y* is null, NH, or O, and Ar is aryl or C1-8heteroaryl;
• X4 is N or CR4;
• X6 is N or CR6;
• R3 is F, Cl, Br, I, NO2, CN, R3a*, OR3a*, SR3a*, N(R3a*)2, SO3R3a*, SO2R3a*, SO2N(R3a*)2, C(O)R3a*;
• C(O)OR3a*, OC(O)R3a*;
• C(O)N(R3a*)2, N(R3a*)C(O)R3a*, OC(O)N(R3a*)2, N(R3a*)C(O)N(R3a*)2, wherein R3a*is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
• wherein two or more of R3a may together form a ring;
• R4 is F, Cl, Br, I, NO2, CN, R4a*, OR4a*, SR4a*, N(R4a*)2, SO4R4a*, SO2R4a*, SO2N(R4a*)2, C(O)R4a*;
• C(O)OR4a*, OC(O)R4a*;
• C(O)N(R4a*)2, N(R4a*)C(O)R4a*, OC(O)N(R4a*)2, N(R4a*)C(O)N(R4a*)2, wherein R4a*is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
• wherein two or more of R4a may together form a ring;
• R5 is F, Cl, Br, I, NO2, CN, R5a*, OR5a*, SR5a*, N(R5a*)2, SO5R5a*, SO2R5a*, SO2N(R5a*)2, C(O)R5a*;
• C(O)OR5a*, OC(O)R5a*;
• C(O)N(R5a*)2, N(R5a*)C(O)R5a*, OC(O)N(R5a*)2, N(R5a*)C(O)N(R5a*)2, wherein R5a*is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
• wherein two or more of R5a may together form a ring;
• R6 is F, Cl, Br, I, NO2, CN, R6a*, OR6a*, SR6a*, N(R6a*)2, SO6R6a*, SO2R6a*, SO2N(R6a*)2, C(O)R6a*;
• C(O)OR6a*, OC(O)R6a*;
• C(O)N(R6a*)2, N(R6a*)C(O)R6a*, OC(O)N(R6a*)2, N(R6a*)C(O)N(R6a*)2, wherein R6a*is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
• wherein two or more of R6a may together form a ring;
• Ar1 is aryl or C1-8heteroaryl;
• Ar2 is aryl or C1-8heteroaryl;
• Ar is C6aryl C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
• and
• R5 is C(O)OR5* or C(O)N(R5*)2, preferably C(O)N(R5*)2, wherein R5* is independently selected from H, C1-8alkyl, and C3-8cycloalkyl.

A compound having the formula:

• or pharmaceutically acceptable salt thereof, wherein
• Z1 is selected from null, CH2, CH2CH2, O, NRn1, S, C(═O), OC(═O), NRn1(═O),
• Ra is selected from C1-8alkyl, C3-8cycloalkyl, C6-12aryl, C2-12heterocyclyl, C1-12heteroaryl, wherein
• Ra may be substituted one or more times by F, Cl, Br, I, C1-4alkyl, aryl, heteroaryl, OH, COOH, CN, NH2, NHC1-8alkyl, N(C1-8alkyl)2, or OC1-8alkyl,
• wherein Ra and Rn1 may together form a ring;
• and
• Z2 is selected from null, CH2, CH2CH2, O, NRn2, S, C(═O), OC(═O), NRn2(═O),
• Rb is selected from C1-8alkyl, OC1-5alkyl, NHC1-8alkyl, N(C1-5alkyl)2, C3-8cycloalkyl, C6-12aryl, C2-12heterocyclyl, C1-12heteroaryl, wherein Rb may be substituted one or more times by F, Cl, Br, I, C1-4alkyl, aryl, heteroaryl, OH, COOH, CN, NH2, NHC1-8alkyl, N(C1-5alkyl)2, or OC1-8alkyl,
• wherein Rb and Rn2 may together form a ring;
• or
• a compound having the formula:
• or a pharmaceutically acceptable salt thereof, wherein:
• Rh is selected from F, Cl, Br, I, NO2, CN, Rh*, ORh*, SRh*, N(Rh*)2, SO3Rh*, SO2Rh*, SO2N(Rh*)2, C(O)Rh*, C(O)ORh*, OC(O)Rh*, C(O)N(Rh*)2, N(Rh*)C(O)Rh*, OC(O)N(Rh*)2, N(Rh*)C(O)N(Rh*)2, or N(Rh*)C(S)N(Rh*)2, wherein Rh* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
• wherein two or more of Rh* may together form a ring, wherein Rh* may be substituted one or more times by Rz4.
• Ri is selected from F, Cl, Br, I, NO2, CN, Ri*, ORi*, SRi*, N(Ri*)2, SO3Ri*, SO2Ri*, SO2N(Ri)2, C(O)Ri*, C(O)ORi*, OC(O)Ri*, C(O)N(Ri*)2, N(Ri*)C(O)Ri*, OC(O)N(Ri*)2, N(Ri*)C(O)N(Ri*)2, or N(Ri*)C(S)N(Ri*)2, wherein Ri*is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
• wherein two or more of Ri* may together form a ring, wherein Ri* may be substituted one or more times by Rz4.
• Ri is selected from F, Cl, Br, I, NO2, CN, Ri*, ORi*, SRi*, N(Ri*)2, SO3Ri*, SO2Ri*, SO2N(Ri*)2, C(O)Ri*, C(O)ORi*, OC(O)Ri*, C(O)N(Ri*)2, N(Ri*)C(O)Ri*, OC(O)N(Ri*)2, N(Ri*)C(O)N(Ri*)2, or N(Ri*)C(S)N(Ri*)2, wherein Ri* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
• wherein two or more of Ri* may together form a ring, wherein Ri* may be substituted one or more times by Rz4.
• Rk is selected from F, Cl, Br, I, NO2, CN, Rk*, ORk*, SRk*, N(Rk*)2, SO3Rk*, SO2Rk*, SO2N(Rk*)2, C(O)Rk*, C(O)ORk*, OC(O)Rk*, C(O)N(Rk*)2, N(Rk*)C(O)Rk*, OC(O)N(Rk*)2, N(Rk*)C(O)N(Rk*)2, or N(Rk*)C(S)N(Rk*)2, wherein Rk* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
• wherein two or more of Rk* may together form a ring, wherein Rk* may be substituted one or more times by Rz4.
• Rl is selected from F, Cl, Br, I, NO2, CN, Rl*, ORl*, SRl*, N(Rl*)2, SO3Rl*, SO2Rl*, SO2N(Rl*)2, C(O)Rl*, C(O)ORl*, OC(O)Rl*, C(O)N(Rl*)2, N(Rl*)C(O)Rl*, OC(O)N(Rl*)2, N(Rl*)C(O)N(Rl*)2, or N(Rl*)C(S)N(Rl*)2, wherein Rl* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
• wherein two or more of Rl* may together form a ring, wherein Rl* may be substituted one or more times by Rz4.
• Rm is selected from F, Cl, Br, I, NO2, CN, Rm*, ORm*, SRm*, N(Rm*)2, SO3Rm*, SO2Rm*, SO2N(Rm*)2, C(O)Rm*, C(O)ORm*, OC(O)Rm*, C(O)N(Rm*)2, N(Rm*)C(O)Rm*, OC(O)N(Rm*)2, N(Rm*)C(O)N(Rm*)2, or N(Rm*)C(S)N(Rm*)2, wherein Rm* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
• wherein two or more of Rh* may together form a ring, wherein Rm* may be substituted one or more times by Rz4.
• Rn is selected from F, Cl, Br, I, NO2, CN, Rn*, ORn*, SRn*, N(Rn*)2, SO3Rn*, SO2Rn*, SO2N(Rn*)2, C(O)Rn*, C(O)ORn*, OC(O)Rn*, C(O)N(Rn*)2, N(Rn*)C(O)Rn*, OC(O)N(Rn*)2, N(Rn*)C(O)N(Rn*)2, or N(Rn*)C(S)N(Rn*)2, wherein Rn* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
• wherein two or more of Rn* may together form a ring, wherein Rn* may be substituted one or more times by Rz4.
• Ro is selected from F, Cl, Br, I, NO2, CN, Ro*, ORo*, SRo*, N(Ro*)2, SO3Ro*, SO2Ro*, SO2N(Ro*)2, C(O)Ro*, C(O)ORo*, OC(O)Ro*, C(O)N(Ro*)2, N(Ro*)C(O)Ro*, OC(O)N(Ro*)2, N(Ro*)C(O)N(Ro*)2, or N(Ro*)C(S)N(Ro*)2, wherein Ro* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
• wherein two or more of Ro* may together form a ring, wherein Ro* may be substituted one or more times by Rz4.
• Rp is selected from F, Cl, Br, I, NO2, CN, Rp*, ORp*, SRp*, N(Rp*)2, SO3Rp*, SO2Rp*, SO2N(Rp*)2, C(O)Rp*, C(O)ORp*, OC(O)Rp*, C(O)N(Rp*)2, N(Rp*)C(O)Rp*, OC(O)N(Rp*)2, N(RP*)C(O)N(Rp*)2, or N(Rp*)C(S)N(Rp*)2, wherein Rp* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
• wherein two or more of Rp* may together form a ring, wherein Rp* may be substituted one or more times by Rz4.
• Rq is selected from F, Cl, Br, I, NO2, CN, Rq*, ORq*, SRq*, N(Rq*)2, SO3Rq*, SO2Rq*, SO2N(Rq*)2, C(O)Rq*, C(O)ORq*, OC(O)Rq*, C(O)N(Rq*)2, N(Rq*)C(O)Rq*, OC(O)N(Rq*)2, N(Rq*)C(O)N(Rq*)2, or N(Rq*)C(S)N(Rq*)2, wherein Rq* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
• wherein two or more of Rq* may together form a ring, wherein Rq* may be substituted one or more times by Rz4;
• and
• Rz4 is in each case independently selected from F, Cl, Br, I, C1-4alkyl, aryl, heteroaryl, OH, OC1-4alkyl, NH2, NHC1-4alkyl, or N(C1-4alkyl)2;
• or
• a compound having the formula:
• or pharmaceutically acceptable salt thereof, wherein
• Ar is C6aryl C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
• and
• R5 is C(O)OR5* or C(O)N(R5*)2, preferably C(O)N(R5*)2, wherein R5* is independently selected from H, C1-8alkyl, and C3-8cycloalkyl;
• or
• a compound having the formula:
• or a pharmaceutically acceptable salt thereof, wherein:
• R1 is OR1a or N(R1a)2, wherein R1a is in each case independently selected from H, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
• R2 is H or OH;
• Z is Z1—X, wherein Z1 is null, NH, S, O, CH2, CH2O, OCH2, OCH2O, CH2NH, NHCH2, CH2S, SCH2, X is P(O)(ORp)2, SO2N(Rp)2, SO2Rp*, wherein Rp is in each case independently selected from H or C1-8alkyl, and Rp* is C1-8alkyl;
• or
• a compound having the formula:
• one of Y1 and Y2 is NH2, and the other is Y*—Ar, wherein Y* is null, NH, or O, and Ar is aryl or C1-8heteroaryl;
• X4 is N or CR4;
• X6 is N or CR6;
• R3 is is F, Cl, Br, I, NO2, CN, R3a*, OR3a*, SR3a*, N(R3a*)2, SO3R3a*, SO2R3a*, SO2N(R3a*)2, C(O)R3a*;
• C(O)OR3a*, OC(O)R3a*;
• C(O)N(R3a*)2, N(R3a*)C(O)R3a*, OC(O)N(R3a*)2, N(R3a*)C(O)N(R3a*)2, wherein R3a* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
• wherein two or more of R3a* may together form a ring;
• R4 is is F, Cl, Br, I, NO2, CN, R4a*, OR4a*, SR4a*, N(R4a*)2, SO4R4a*, SO2R4a*, SO2N(R4a*)2, C(O)R4a*;
• C(O)OR4a*, OC(O)R4a*;
• C(O)N(R4a*)2, N(R4a*)C(O)R4a*, OC(O)N(R4a*)2, N(R4a*)C(O)N(R4a*)2, wherein R4a* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
• wherein two or more of R4a* may together form a ring;
• R5 is is F, Cl, Br, I, NO2, CN, R5a*, OR5a*, SR5a*, N(R5a*)2, SO5R5a*, SO2R5a*, SO2N(R5a*)2, C(O)R5a*;
• C(O)OR5a*, OC(O)R5a*;
• C(O)N(R5a*)2, N(R5a*)C(O)R5a*, OC(O)N(R5a*)2, N(R5a*)C(O)N(R5a*)2, wherein R5a* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
• wherein two or more of R5a* may together form a ring;
• R6 is is F, Cl, Br, I, NO2, CN, R6a*, OR6a*, SR6a*, N(R6a*)2, SO6R6a*, SO2R6a*, SO2N(R6a*)2, C(O)R6a*;
• C(O)OR6a*, OC(O)R6a*;
• C(O)N(R6a*)2, N(R6a*)C(O)R6a*, OC(O)N(R6a*)2, N(R6a*)C(O)N(R6a*)2, wherein R6a* is in each case independently selected from hydrogen, C1-8alkyl, aryl, C1-8heteroaryl, C3-8cycloalkyl, or C1-8heterocyclyl;
• wherein two or more of R6a* may together form a ring;
• Ar1 is aryl or C1-8heteroaryl;
• and
• Ar2 is aryl or C1-8heteroaryl.